Roche. Roche announces positive phase III results for Gazyva/Gazyvaro in primary membranous nephropathy, marking a significant milestone in this autoimmune disease. 2026 Feb 16. Accessed 2026 Feb 16.
During a live event, Hagen Kennecke, MD, discusses how RADIANT-4 and NETTER trials have reshaped NET care with everolimus and ...
( OTCQB: BIXT) today announced positive clinical results from its recently completed Phase 2 randomized, double-blind, placebo-controlled, dose-optimization trial evaluating ProLectin-M in subjects ...
Peer-reviewed Phase 2 Results Inform Ongoing Phase 3/Pivotal Trial of Celeste® in Parkinson’s Disease The Phase 2 study ...
RWD and RWE are reshaping the design of clinical trials, making them smarter, faster, and more efficient. Read more here: ...
The FDA has rejected a rare blood disease candidate from Disc Medicine, a compound that been granted expedited review through ...
FDA proposes MRD-negative and complete response endpoints to fast-track multiple myeloma drug approvals, pushing deeper molecular results over ORR.
Real-time strategy games are usually about conquest. You expand your influence through various means to ultimately crush your opposition, as your economy and military scale out of control. The genre ...
THE VACCINE MAKER MODERNA decided this past week to tell the world about bad news it had received from the federal government ...
NSCLC remains the leading cause of cancer-related mortality worldwide, with EGFR mutations being a critical driver in approximately 10-15% of lung adenocarcinomas in Western populations, and up to 40% ...
This engagement begins as a defined pilot, with a clear path to expand into a multi-study commercial relationship based on results. For Lunai, this is the kind of near-term work that can translate ...
Most return-to-office mandates aren’t solving a collaboration problem. They’re solving an assessment problem that physical presence has been masking.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results